Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001
Paul D. Brown(Mayo Clinic), Jeffrey S. Wefel(The University of Texas MD Anderson Cancer Center), Deborah Watkins Bruner(Emory University), Harold Yoon(Heartland Cancer Research), André Konski(Hospital of the University of Pennsylvania), Kiran Devisetty(Wayne State University), Baldassarre Stea(University of Arizona), Bethany Anderson(UW Health University Hospital), Vinai Gondi(Thomas Jefferson University Hospital), Wolfgang A. Tomé(Albert Einstein College of Medicine), Tim J. Kruser(Northwestern Memorial Hospital), Kenneth Y. Usuki(University of Rochester), David Roberge(Centre Hospitalier de l’Université de Montréal), Deepak Khuntia(Mills Peninsula Health Services), Terri S. Armstrong(The University of Texas MD Anderson Cancer Center), David R. Grosshans(The University of Texas MD Anderson Cancer Center), Minesh P. Mehta(Columbia University), Steven J. Chmura(University of Chicago), Wenyin Shi(Thomas Jefferson University Hospital), Mark R. Gilbert(Johns Hopkins University SAIS Bologna Center), Nadia N. Laack(Mayo Clinic), Joseph Bovi(Froedtert Hospital), Vijayananda Kundapur(Thomas Jefferson University Hospital), Lisa A. Kachnic(NewYork–Presbyterian Hospital), Clifford G. Robinson(Barnes-Jewish Hospital), Jing Li(The University of Texas MD Anderson Cancer Center), Snehal Deshmukh(NRG Oncology), Stephanie L. Pugh(American College of Radiology), Tammie L.S. Benzinger(Washington University in St. Louis), Sunjay Shah(Thomas Jefferson University Hospital)
Cited by 827
Related Papers
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial
|The Lancet|2004|2.4k
Summary Report on the Graded Prognostic Assessment: An Accurate and Facile Diagnosis-Specific Tool to Estimate Survival for Patients With Brain Metastases
|Journal of Clinical Oncology|2011|1.4k
Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402
|Journal of Clinical Oncology|2012|1.2k